title: Lithium augmentation of topiramate for bipolar disorder with comorbid binge eating disorder and obesity.
abstract: OBJECTIVE
  To evaluate the effectiveness of lithium augmentation of topiramate on mood symptoms, binge eating behavior, and body weight in obese bipolar patients with binge eating disorder (BED) seeking weight management.
  
  
  METHODS
  We conducted a naturalistic study of 12 consecutive outpatients with bipolar disorders, BED, and obesity who received lithium augmentation for mood instability during the course of topiramate-based pharmacotherapy for obesity and BED. Lithium was added to topiramate (mean dose 514 mg i.d.) and titrated to a mean dose of 1009 mg i.d. (mean plasma concentration 0.7 mmol/L). Treatment response was assessed by comparing changes in clinical severity scales for mood and eating disorders, weekly binge eating frequency, and weight for the 2 months before and the first 2 months during lithium treatment.
  
  
  RESULTS
  A statistically significant improvement in global severity of mood symptoms was observed after as compared to before lithium augmentation. Statistically insignificant reductions in weight and in binge frequency and severity were also observed after lithium addition.
  
  
  CONCLUSIONS
  Optimal weight loss treatment in obese patients with comorbid bipolar and BEDs may require stabilization of mood. The combination of lithium and topiramate may have a role in the management of this difficult-to-treat population.
authors.affiliation: Department of Psychiatry, Psychopharmacology Research Program, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0559, USA. renu.kotwal@uc.edu
authors.forename: Renu
authors.initials: R
authors.lastname: Kotwal
authors.forename: Anna
authors.initials: A
authors.lastname: Guerdjikova
authors.forename: Susan L
authors.initials: SL
authors.lastname: McElroy
authors.forename: Paul E
authors.initials: PE
authors.lastname: Keck
mesh_terms: D000328:Adult; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D018692:Antimanic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000453:epidemiology; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D052018:Bulimia Nervosa / Q000188:drug therapy* / Q000453:epidemiology; D015897:Comorbidity; D004347:Drug Interactions; D005260:Female; D005500:Follow-Up Studies; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D018021:Lithium Chloride / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy* / Q000453:epidemiology; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D011795:Surveys and Questionnaires; D000077236:Topiramate
chemical_list: D019440:Anti-Obesity Agents; D018692:Antimanic Agents; D000077236:Topiramate; D005632:Fructose; D018021:Lithium Chloride